Healthcare · NIFTY 500

Divi's Laboratories Limited

NSEDIVISLAB BSE532488 ISININE361B01024 SeriesEQ Listed on NSE · BSE

₹11,485.00 +118.00 (+1.04%) Updated 12 Nov, 6:47 pm IST

Open chart Back to screener

Price, daily close+51.67% in a year

Today

Open: ₹11,329.00
Prev close: ₹11,367.00
Day high: ₹11,485.00
Day low: ₹11,272.00
Volume: 7.29 L
Value traded: ₹830.53 Cr
Upper circuit: ₹11,771.00
Lower circuit: ₹11,086.00
52W high: ₹11,485.00
52W low: ₹5,647.50
1 month: +10.25%
6 months: +53.72%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹304,353 Cr

P/E (TTM)90.63

P/B16.91

Book value / share₹679.13

EPS (TTM)₹126.73

ROE18.7%

Dividend yield0.26%

Dividend (12m)₹30.00 / share

Net margin (TTM)27.6%

Operating margin42.6%

Debt / equity—

Current ratio4.60

EV / EBITDA66.52

Sales growth (YoY qtr)+35.40%

Profit growth (YoY qtr)+63.57%

Sales CAGR 3Y+10.78%

Profit CAGR 3Y+12.09%

Shares26.50 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

1,855358

Dec 23

2,303538

Mar 24

2,118430

Jun 24

2,338510

Sep 24

2,319589

Dec 24

2,585662

Mar 25

2,410545

Jun 25

2,715689

Sep 25

2,604583

Dec 25

2,831751

Mar 26

3,080902

Jun 26

3,6761,127

Sep 26

Revenue · QoQ (vs last quarter)

—+24%-8.0%+10%-0.8%+11%-6.8%+13%-4.1%+8.7%+8.8%+19%

Revenue · YoY (vs a year ago)

————+25%+12%+14%+16%+12%+9.5%+28%+35%

Net profit · QoQ (vs last quarter)

—+50%-20%+19%+15%+12%-18%+26%-15%+29%+20%+25%

Net profit · YoY (vs a year ago)

————+65%+23%+27%+35%-1.0%+13%+66%+64%

RevenueNet profitLine = trend

13.50

Dec 23

20.25

Mar 24

16.20

Jun 24

19.20

Sep 24

22.20

Dec 24

24.93

Mar 25

20.49

Jun 25

25.97

Sep 25

21.98

Dec 25

28.31

Mar 26

33.95

Jun 26

42.49

Sep 26

EPS (₹) · YoY (vs a year ago)

————+64%+23%+26%+35%-1.0%+14%+66%+64%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	1,855	2,303	2,118	2,338	2,319	2,585	2,410	2,715	2,604	2,831	3,080	3,676
Other income	95.0	79.0	79.0	106	82.0	86.0	119	145	88.0	155	64.0	94.0
Total income	1,950	2,382	2,197	2,444	2,401	2,671	2,529	2,860	2,692	2,986	3,144	3,770
Raw material	794	898	893	976	1,021	931	1,010	937	1,217	1,214	1,503	1,812
Purchases	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Employee cost	268	297	292	304	297	350	340	354	367	381	408	444
Other expenses	369	373	351	349	357	368	385	400	402	397	431	485
Total expenses	1,461	1,669	1,593	1,722	1,675	1,807	1,796	1,948	1,838	2,023	1,964	2,265
Operating profit	489	731	622	716	743	886	729	888	816	934	1,255	1,566
OPM %	26.4%	31.7%	29.4%	30.6%	32.0%	34.3%	30.2%	32.7%	31.3%	33.0%	40.7%	42.6%
Finance cost	0.0	2.0	0.0	1.0	0.0	1.0	3.0	8.0	6.0	6.0	6.0	13.0
Depreciation	95.0	95.0	97.0	99.0	99.0	107	112	113	118	120	133	142
Exceptional items	—	—	—	—	—	—	—	—	-74.0	—	—	—
Profit before tax	489	713	604	722	726	864	733	912	780	963	1,180	1,505
Tax	131	175	174	212	137	202	188	223	197	212	278	378
Net profit	358	538	430	510	589	662	545	689	583	751	902	1,127
Profit to shareholders	358	538	430	510	589	662	545	689	583	751	902	1,127
EPS (₹)	13.50	20.25	16.20	19.20	22.20	24.93	20.49	25.97	21.98	28.31	33.95	42.49

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

4,9461,8720.0

FY19

5,3941,8221,377

FY20

6,9692,8601,984

FY21

8,9603,8822,960

FY22

7,7682,3681,823

FY23

7,8452,2051,600

FY24

9,3602,9682,191

FY25

10,5603,3672,568

FY26

Revenue · YoY (vs a year ago)

—+9.1%+29%+29%-13%+1.0%+19%+13%

Net profit · YoY (vs a year ago)

——+44%+49%-38%-12%+37%+17%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	4,946	5,394	6,969	8,960	7,768	7,845	9,360	10,560
Other income	156	190	62.6	114	345	339	352	507
Total expenses	3,247	3,765	4,366	5,390	5,744	6,021	6,796	7,605
Employee cost	542	621	826	946	975	1,094	1,243	1,442
Operating profit	1,872	1,822	2,860	3,882	2,368	2,205	2,968	3,367
OPM %	37.8%	33.8%	41.0%	43.3%	30.5%	28.1%	31.7%	31.9%
Finance cost	3.5	6.1	0.9	0.8	0.7	3.0	2.0	23.0
Depreciation	169	186	256	312	343	378	402	463
Profit before tax	1,855	1,819	2,666	3,684	2,369	2,163	2,916	3,388
Tax	502	443	682	723	545	563	725	820
Tax rate %	27.1%	24.3%	25.6%	19.6%	23.0%	26.0%	24.9%	24.2%
Net profit	1,353	1,377	1,984	2,960	1,823	1,600	2,191	2,568
Profit to shareholders	0.0	—	1,984	2,960	1,823	1,600	2,191	2,568
Net margin %	0.0%	25.5%	28.5%	33.0%	23.5%	20.4%	23.4%	24.3%
EPS (₹)	50.96	51.85	74.75	111.52	68.69	60.27	82.53	96.75

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

12,767170

Mar 23

13,571363

Mar 24

14,9692.0415

Mar 25

16,761128

Mar 26

17,997303

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+6.3%+10%+12%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	12,767	13,571	14,969	16,761	17,997
Long-term borrowings	0.0	0.0	0.0	0.0	0.0
Short-term borrowings	0.0	0.0	2.0	0.0	0.0
Total borrowings	—	—	2.0	—	—
Current liabilities	1,101	1,278	1,452	2,043	2,707
Fixed assets (PPE)	4,714	4,733	5,437	6,515	7,452
Inventories	3,000	3,184	3,236	3,954	5,540
Trade receivables	1,793	2,156	2,731	2,984	3,487
Cash & equivalents	170	363	415	128	303
Current assets	9,312	9,675	10,081	11,096	12,439
Total assets	14,439	15,470	16,932	20,033	21,964
Debt / equity	—	—	0.00	—	—

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

1,912-2,195-532

FY22

2,460-2,708-797

FY23

1,261-269-799

FY24

1,653-804-799

FY25

2,738-2,219-804

FY26

Operations · YoY (vs a year ago)

—+29%-49%+31%+66%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,912	2,460	1,261	1,653	2,738
Cash from investing	-2,195	-2,708	-269	-804	-2,219
Cash from financing	-532	-797	-799	-799	-804
Spent on fixed assets	-713	-473	-1,003	-1,438	-2,520
Free cash flow	1,199	1,987	258	215	218
Net cash flow	-816	-1,045	193	50.0	-285

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

51.9%Dec 23

51.9%Mar 24

51.9%Jun 24

51.9%Sep 24

51.9%Dec 24

51.9%Mar 25

51.9%Jun 25

51.9%Sep 25

51.9%Dec 25

51.9%Mar 26

51.9%Jun 26

51.9%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

51.9%promoter

Promoter & group: 51.88%
Public (FIIs, mutual funds, retail…): 48.12%
Promoter change, last quarter: 0.00 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 30 Per ShareEx 24-Jul-2026
Dividend - Rs 30 Per ShareEx 25-Jul-2025
Dividend - Rs 30 Per ShareEx 02-Aug-2024
Dividend - Rs 30 Per ShareEx 11-Aug-2023
Dividend - Rs 30 Per ShareEx 11-Aug-2022
Dividend - Rs 20 Per ShareEx 17-Aug-2021
Annual General MeetingEx 04-Sep-2020
Interim Dividend - Rs 16 Per ShareEx 25-Feb-2020

Board meetings

the financial results for the period ended September 30, 202607-Nov-2026
Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited …07-Nov-2026
Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 01-Aug-2026 to inter-alia consider and approve the Unaudited …01-Aug-2026
the financial results for the period ended Jun 30, 202601-Aug-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.23-May-2026

Filings with NSE

Copy of Newspaper Publication9 Nov
Outcome of Board Meeting7 Nov
Certificate under SEBI (Depositories and Participants) Regulations, 20186 Oct
Trading Window30 Sep
Copy of Newspaper Publication12 Sep
Shareholders meeting10 Aug
Analysts/Institutional Investor Meet/Con. Call Updates6 Aug

Latest news

Divi's Laboratories shares hit 52-week high on robust Q2 earnings; analysts flag growth opportunitiesUpstox · 9 Nov, 1:44 pm Divis joins ₹3 trn market cap club; rallies 15% in 2 days post Q2 resultsBusiness Standard · 9 Nov, 10:02 am Nifty 500: Divi's Labs hits record high as profit jumps 64%; HFCL, TD Power slide at market openCNBC TV18 · 9 Nov, 10:02 am Results: Divi's Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its EstimatesSimply Wall St · 10 Nov, 6:11 am Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pm Divis Laboratories Share Price - Live NSE: DIVISLAB Stock Price & ChartUpstox · 11 Nov, 12:19 am DIVISLAB Outlook for the WeekEquitypandit · 8 Nov, 1:30 pm Why Divi's Laboratories Share Price is RisingEquitymaster · 9 Nov, 1:46 pm

About

About Divi's Laboratories Limited

Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Divi's Laboratories Limited
NSE symbol: DIVISLAB
BSE scrip code: 532488
ISIN: INE361B01024
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 12 Mar 2003
Face value: ₹2 per share
Market lot: 1 share
Shares issued: 26.50 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Kiran S. Divi
Chair: Ramesh B. V. Nimmagadda
Headquarters: Hyderabad, Telangana, India
Registered address: Divi Towers,1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India
Founded: 1990
Employees: 19,292
Financial year: April to March
Results basis: Consolidated
Website: divislabs.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Divi's Laboratories Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers